Clinical trials: Resistant Hypertension
Metabolic Syndrome X, Overweight
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
Metabolic syndrome consists of a group of co-occuring conditions that increase an individual's risk of developing heart disease, stroke, and diabetes.
- Conditions
- Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias
- Trial name
- ARCH-MS (NCT00455325)
- Testing
- Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Washington University School of Medicine
Obesity, Hypertension
The Effects of Metformin on Blood Vessel Structure and Function
The purpose of this study is to evaluate whether the drug Metformin has beneficial effects on the blood vessels of individuals with the Metabolic Syndrome (MeS).
- Conditions
- Obesity, Hypertension, Hypercholesterolemia, Hyperglycemia
- Trial name
- NCT00105066
- Testing
- Metformin
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- National Institute on Aging (NIA)
Hypertension
Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients
This is a prospective, multicenter, feasibility study on the safety and efficacy of renal denervation in patients with resistant hypertension.
- Trial name
- EnligHTN-I (NCT01438229)
- Testing
- St. Jude Medical renal artery ablation system: RF ablation generator (IBI 1500T11.5) and Renal artery ablation catheter (DS3D001, DS3D002)
- Where
- 4 sites in Australia, Greece
- Volunteers
- 47 people
- Sponsor
- Abbott Medical Devices
Pulmonary Arterial Hypertension
A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002)
This study of frespaciguat in participants with Group 1 pulmonary arterial hypertension (PAH) will assess the safety, tolerability and pharmacokinetics (PK) of inhaled frespaciguat. There is no formal hypothesis to be tested.
- Trial name
- NCT03744637
- Testing
- Frespaciguat
- Where
- Moldova
- Volunteers
- 25 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Aldosteronism, Resistant Hypertension
Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension
Primary aldosteronism (PA) is common but rarely recognized cause of hypertension that carries excess cardiovascular and renal risk and has approved targeted treatments.
- Conditions
- Primary Aldosteronism, Resistant Hypertension, Secondary Hypertension, Hyperaldosteronism
- Trial name
- ALERT-PA (NCT05925569)
- Testing
- Best Practice Advisory Computerized Alert
- Where
- United States
- Volunteers
- 12,501 people
- Sponsor
- Brigham and Women's Hospital
Hypertension, Renal
RENABLATE-II Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension - 157
This is a prospective, multi-center, non-randomized, feasibility study to assess the safety and effectiveness of renal artery sympathetic denervation using the investigational devices in subjects with resistant hypertension.
- Trial name
- RENABLATE-II (NCT02095691)
- Testing
- Celsius® ThermoCool® Renal Denervation
- Volunteers
- 19 people
- Sponsor
- Biosense Webster, Inc.